Literature DB >> 22552780

Cannabinoid 2 (CB2) receptor involvement in the down-regulation but not up-regulation of serum IgE levels in immunized mice.

Catherine A Newton1, Thomas W Klein.   

Abstract

Marijuana cannabinoids such as Δ(9)-tetrahydrocannabinol (THC) have been shown in experimental systems to bias T helper immunity towards Th2 and away from Th1. This effect if broadly applicable to humans could have important implications in Th2-mediated diseases such as allergy. In the current study, we examined the effect of cannabinoids on serum immunoglobulin IgE levels in immunized mice and also examined the role of cannabinoid receptors in the response. The method involved pre-injecting mice with cannabinoid receptor agonists and antagonists followed 18-24 h later with an immunizing injection with two different antigen/adjuvant combinations. This treatment was followed 2-3 weeks later with a booster injection of antigen and the subsequent bleeding of mice 1-2 weeks later for serum immunoglobulin analysis by ELISA. Our results showed that THC injection enhanced total IgE serum levels in response to antigen immunization even under conditions of deficient cannabinoid receptor 2 (CB2) and cannabinoid receptor 1 (CB1) activity and furthermore the increase in IgE was accompanied by a decrease in serum IgG2a. In addition, we observed that l-α-lysophosphatidyliniositol (LPI) increased serum IgE levels and that IgE levels were higher in CB2 deficient mice and suppressed by the CB2 agonist, Gp1a. These results suggest that in this IgE induction model in mice, non-selective cannabinoids such as THC increase IgE through receptors other than CB1 and CB2 but that CB2 receptors do play a suppressive role in the control of serum IgE levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552780      PMCID: PMC3419805          DOI: 10.1007/s11481-012-9361-4

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  26 in total

Review 1.  Pharmacological characterization of GPR55, a putative cannabinoid receptor.

Authors:  Haleli Sharir; Mary E Abood
Journal:  Pharmacol Ther       Date:  2010-03-16       Impact factor: 12.310

2.  Intact humoral and cell-mediated immunity in chronic marijuana smoking.

Authors:  G S Rachelefsky; G Opelz; M R Mickey; P Lessin; M Kiuchi; M J Silverstein; E R Stiehm
Journal:  J Allergy Clin Immunol       Date:  1976-10       Impact factor: 10.793

3.  Morphine directs T cells toward T(H2) differentiation.

Authors:  S Roy; S Balasubramanian; S Sumandeep; R Charboneau; J Wang; D Melnyk; G J Beilman; R Vatassery; R A Barke
Journal:  Surgery       Date:  2001-08       Impact factor: 3.982

4.  Prostaglandin E2 promotes IL-4-induced IgE and IgG1 synthesis.

Authors:  R L Roper; D H Conrad; D M Brown; G L Warner; R P Phipps
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

5.  Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection.

Authors:  T W Klein; C A Newton; N Nakachi; H Friedman
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

6.  Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice.

Authors:  Tong-Rong Jan; Aimen K Farraj; Jack R Harkema; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2003-04-01       Impact factor: 4.219

7.  Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.

Authors:  L X Zhu; S Sharma; M Stolina; B Gardner; M D Roth; D P Tashkin; S M Dubinett
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

Review 8.  Cannabinoids and neuroinflammation.

Authors:  Lisa Walter; Nephi Stella
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

9.  Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection.

Authors:  C A Newton; T W Klein; H Friedman
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

Review 10.  Effects of delta-9-tetrahydrocannabinol on human immune function and host defense.

Authors:  Michael D Roth; Gayle C Baldwin; Donald P Tashkin
Journal:  Chem Phys Lipids       Date:  2002-12-31       Impact factor: 3.329

View more
  6 in total

1.  Chronic Δ(9)-Tetrahydrocannabinol Administration Reduces IgE(+)B Cells but Unlikely Enhances Pathogenic SIVmac251 Infection in Male Rhesus Macaques of Chinese Origin.

Authors:  Qiang Wei; Li Liu; Zhe Cong; Xiaoxian Wu; Hui Wang; Chuan Qin; Patricia Molina; Zhiwei Chen
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-25       Impact factor: 4.147

2.  Δ(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection.

Authors:  Julie C Williams; Sofia Appelberg; Bruce A Goldberger; Thomas W Klein; John W Sleasman; Maureen M Goodenow
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-23       Impact factor: 4.147

3.  Impact of Δ9-Tetrahydrocannabinol on Rheumatoid Arthritis Synovial Fibroblasts Alone and in Co-Culture with Peripheral Blood Mononuclear Cells.

Authors:  Torsten Lowin; Christina Kok; Sophie Smutny; Georg Pongratz
Journal:  Biomedicines       Date:  2022-05-11

4.  Cannabinoid Receptor 2 (CB2) Plays a Role in the Generation of Germinal Center and Memory B Cells, but Not in the Production of Antigen-Specific IgG and IgM, in Response to T-dependent Antigens.

Authors:  Sreemanti Basu; Avijit Ray; Bonnie N Dittel
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

5.  Cannabinoid receptor CB2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide in MG-63 cells.

Authors:  Lei Yang; Fei-Fei Li; Yu-Chen Han; Bin Jia; Yin Ding
Journal:  Mediators Inflamm       Date:  2015-01-14       Impact factor: 4.711

6.  Effect of Delta-9-tetrahydrocannabinol on mouse resistance to systemic Candida albicans infection.

Authors:  Gideon W Blumstein; Arya Parsa; Anthony K Park; Beverly L P McDowell; Melissa Arroyo-Mendoza; Marie Girguis; Jill P Adler-Moore; Jon Olson; Nancy E Buckley
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.